The IgA pneumococcal antibody responses to each of the pneumococcal serotypes in a 14‐valent pneumococcal polysaccharide vaccine, and the total serum IgA concentration, have been examined in 21 individuals splenectomized because of trauma and in 10 control individuals. Both groups of individuals showed significant IgA antibody responses to most of the serotypes, but the splenectomized individuals tended to have somewhat lower IgA pneumococcal antibody levels than did the control individuals. This difference may possibly be related to age differences between the groups. Our results therefore seem compatible with the hypothesis that the serum IgA antipneumococcal antibody response is not affected by splenectomy.

01 May 1986·Acta Paediatrica

IgG and IgM Antibody Responses to Pneumococcal Vaccination in Splenectomized Children and in Children Who Had Non‐Operative Management of Splenic Rupture

Article

Author: T. Linné ; M. Eriksson ; M. Kalin ; B. Jakobsson ; P. Tordai ; K. Lännergren ; K.-M. Lundmark

ABSTRACT. The IgG and IgM type specific anticapsular pneumococcal antibody titres were studied with ELISA during one year following vaccination with a 14‐valent pneumococcal polysaccharide vaccine in four different patient groups: 41 children splenectomized after a traumatic rupture, 16 splenectomized because of disease, 15 non‐surgically managed after splenic rupture, and 19 healthy controls. Serum samples were obtained before vaccination and after 14, 60, 180, and 360 days. The IgG antibody responses were equally good in all of the patient groups, while the IgM antibody responses were less pronounced in the splenectomized. In the non‐surgically managed patients, the IgM antibody titres after vaccination, as well as antibody responses per se, were significantly higher for all 12 pneumococcal types studied than in the patients who were splenectomized. Both the IgG and the IgM antibody titres were highest at 14 days after vaccination. However, while the IgG titres for most pneumococcal types remained elevated at 360 days, the IgM titres soon fell to prevaccination levels. The antibody response was less good for the types 3 and 6 A. The results indicate that the IgG antibody response to pneumococcal polysaccharide vaccination is unaffected in splenectomized individuals, but the IgM antibody response is decreased. In patients with a healed traumatically damaged spleen, both the IgG and IgM responses seem to be normal.

01 Sep 1983·Acta Pathologica Microbiologica Scandinavica Series B: Microbiology

Serotypes, Incidence and Outcome

Article

Author: Freddy Karup Pedersen ; Jørgen Henrichsen

The incidence of pneumoccal meningitis in Danish children during 1969–1978 was estimated to be 2.1/year/100,000 children from 0 to 14 years old. Fifty‐five per cent of 146 children with pneumococcal meningitis and 61% of 61 with bacteraemia were below 2 years of age. Mortality from meningitis was 13% and from bacteraemia 7%. Of the children with meningitis, 14% had sequelae at the time of discharge from the hospital. Sequelae were not seen after bacteraemia. Among 277 pneumococcal isolates from spinal fluid and blood from Danish children during 1969–1978, serotypes 14, 18C, 6A + 6B, 23F, 7F and 19F, in that order of frequency, were the most common ones, accounting for 69% of all isolates. Serotypes included in current 14‐valent pneumococcal polysaccharide vaccines made up 81% of all types, when types 6A and 6B are considered together (because it has been shown that they offer cross‐protection).

100 Deals associated with 24 valent pneumococcal polysaccharide conjugate vaccine(MSD)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Streptococcal Infections	Preclinical	US	Hangzhou MSD Pharmaceutical Co. Ltd.	22 May 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

24 valent pneumococcal polysaccharide conjugate vaccine(MSD)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation